| 221 | Humans |
| 140 | Female |
| 110 | Male |
| 108 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 104 | Middle Aged |
| 98 | Arthritis, Rheumatoid (drug therapy) |
| 81 | Adult |
| 79 | Treatment Outcome |
| 75 | Antirheumatic Agents (therapeutic use) |
| 65 | Aged |
| 50 | Chronic |
| 49 | Tocilizumab |
| 47 | Rheumatology |
| 47 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 45 | Rheumatoid arthritis |
| 45 | Immunomodulator |
| 38 | Antirheumatic Agents (adverse effects) |
| 37 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 34 | Treatment |
| 33 | Drug Therapy, Combination |
| 32 | Severity of Illness Index |
| 28 | Antibodies, Monoclonal (therapeutic use) |
| 27 | Immunosuppressive agent |
| 26 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
| 25 | Retrospective Studies |
| 25 | Biotherapy |
| 24 | Glucocorticoids (therapeutic use) |
| 23 | Biological Products (therapeutic use) |
| 23 | Antibodies, Monoclonal, Humanized |
| 22 | Immunosuppressive Agents (therapeutic use) |
| 22 | Antirheumatic Agents (administration & dosage) |
| 22 | Antibodies, Monoclonal, Humanized (pharmacology) |
| 21 | Methotrexate (therapeutic use) |
| 19 | Interleukin-6 (antagonists & inhibitors) |
| 18 | Receptors, Interleukin-6 (antagonists & inhibitors) |
| 18 | Prospective Studies |
| 18 | Adolescent |
| 15 | Remission Induction |
| 15 | Human |
| 15 | Follow-Up Studies |
| 15 | Arthritis, Rheumatoid (diagnosis) |
| 14 | Young Adult |
| 14 | Interleukin 6 |
| 14 | Giant Cell Arteritis (drug therapy) |
| 14 | Arthritis, Rheumatoid (immunology) |
| 13 | Double-Blind Method |
| 13 | Child |
| 13 | Biological Products (adverse effects) |
| 13 | Antirheumatic agent |
| 12 | Time Factors |
| 12 | Arthritis, Rheumatoid (complications) |
| 12 | Antibodies, Monoclonal (adverse effects) |
| 12 | Animals |
| 11 | tocilizumab |
| 11 | Prognosis |
| 11 | Prednisone (therapeutic use) |
| 11 | Disease Progression |
| 11 | Arthritis, Rheumatoid (blood) |
| 10 | Still's Disease, Adult-Onset (drug therapy) |
| 10 | Rituximab |
| 10 | Rituximab (therapeutic use) |
| 10 | Risk Factors |
| 10 | France |
| 10 | Antineoplastic agent |
| 10 | Adrenal Cortex Hormones (therapeutic use) |
| 10 | Abatacept |
| 10 | Abatacept (therapeutic use) |
| 9 | Drug Resistance |
| 9 | Arthritis, Rheumatoid (pathology) |
| 9 | Arthritis, Juvenile (drug therapy) |
| 9 | Aged, 80 and over |
| 8 | Takayasu Arteritis (drug therapy) |
| 8 | Rituximab (adverse effects) |
| 8 | Risk Assessment |
| 8 | Infusions, Intravenous |
| 8 | Biomarkers (blood) |
| 8 | Biological Therapy |
| 7 | Systemic disease |
| 7 | Recurrence |
| 7 | Receptors, Interleukin-6 (immunology) |
| 7 | Radiography |
| 7 | Polychondritis, Relapsing (drug therapy) |
| 7 | Injections, Subcutaneous |
| 7 | Inflammatory joint disease |
| 7 | Immunologic Factors (therapeutic use) |
| 7 | Glucocorticoids (administration & dosage) |
| 7 | Drug Administration Schedule |
| 7 | Cohort Studies |
| 7 | Child, Preschool |
| 7 | Anti-Inflammatory Agents (therapeutic use) |
| 6 | Spondylarthritis |
| 6 | Randomized Controlled Trials as Topic |
| 6 | Polymyalgia Rheumatica (drug therapy) |
| 6 | Mice |
| 6 | Methotrexate |
| 6 | Inflammation |
| 6 | Biological treatment |
| 6 | Arthritis, Rheumatoid (metabolism) |
| 6 | Antirheumatic Agents (pharmacology) |
| 6 | Anti-Tumor Necrosis Factor-alpha |
| 6 | Adalimumab |
| 6 | Adalimumab (therapeutic use) |
| 5 | rheumatoid arthritis |
| 5 | Vasculitis |
| 5 | Uveitis (drug therapy) |
| 5 | Tumor Necrosis Factor-alpha (metabolism) |
| 5 | Review |
| 5 | Phenotype |
| 5 | Interleukin-6 (immunology) |
| 5 | Infliximab (therapeutic use) |
| 5 | Incidence |
| 5 | Immunocompromised Host |
| 5 | Glucocorticoids (adverse effects) |
| 5 | Etanercept (therapeutic use) |
| 5 | Drug Substitution |
| 5 | Dose-Response Relationship, Drug |
| 5 | Diagnosis, Differential |
| 5 | Cytokine |
| 5 | Clinical Trials as Topic |
| 5 | Chronic Disease |
| 5 | Castleman Disease (drug therapy) |
| 5 | C-Reactive Protein (metabolism) |
| 5 | Biological Factors (therapeutic use) |
| 5 | Behcet Syndrome (drug therapy) |
| 5 | Arthritis, Rheumatoid (diagnostic imaging) |
| 4 | Treatment Failure |
| 4 | Surveys and Questionnaires |
| 4 | Still's Disease, Adult-Onset (diagnosis) |
| 4 | Spondylitis, Ankylosing (drug therapy) |
| 4 | Registries |
| 4 | Refractory |
| 4 | Prednisone (administration & dosage) |
| 4 | Positron-Emission Tomography |
| 4 | Outcome Assessment, Health Care |
| 4 | Multivariate Analysis |
| 4 | Methotrexate (administration & dosage) |
| 4 | Interleukin-6 (metabolism) |
| 4 | Interleukin-6 (blood) |
| 4 | Infection |
| 4 | Immunoconjugates (therapeutic use) |
| 4 | Giant cell arteritis |
| 4 | France (epidemiology) |
| 4 | Etanercept |
| 4 | Drug Monitoring (methods) |
| 4 | Drug Eruptions (etiology) |
| 4 | Disease Models, Animal |
| 4 | Disease Management |
| 4 | Body Mass Index |
| 4 | Blood Sedimentation |
| 4 | Biological agent |
| 4 | Behcet Syndrome (complications) |
| 4 | Arthritis |
| 4 | Arthritis, Rheumatoid (therapy) |
| 4 | Arthritis (drug therapy) |
| 4 | Antipsoriatic agent |
| 4 | Antibodies, Monoclonal, Murine-Derived (therapeutic use) |
| 4 | Antibodies, Monoclonal (administration & dosage) |
| 4 | Abatacept (adverse effects) |
| 3 | human |
| 3 | Uveitis (etiology) |
| 3 | Tumor necrosis factor |
| 3 | Tumor Necrosis Factor-alpha (immunology) |
| 3 | Toxicity |
| 3 | T-Lymphocytes, Regulatory (pathology) |
| 3 | Still's Disease, Adult-Onset (pathology) |
| 3 | Still's Disease, Adult-Onset (complications) |
| 3 | Still disease |
| 3 | Spondylarthritis (drug therapy) |
| 3 | Skin (pathology) |
| 3 | Scleroderma, Systemic (drug therapy) |
| 3 | Rheumatic Diseases (immunology) |
| 3 | Rheumatic Diseases (drug therapy) |
| 3 | Relapsing polychondritis |
| 3 | Receptors, Interleukin-6 (drug effects) |
| 3 | Psoriasis |
| 3 | Psoriasis (chemically induced) |
| 3 | Prednisone (adverse effects) |
| 3 | Polymyalgia Rheumatica (diagnostic imaging) |
| 3 | Network Meta-Analysis |
| 3 | Malignant tumor |
| 3 | Macrophage activation syndrome |
| 3 | Longitudinal Studies |
| 3 | Juvenile rheumatoid arthritis |
| 3 | Joints (physiopathology) |
| 3 | Joints (pathology) |
| 3 | Interleukin-6 (physiology) |
| 3 | Interleukin-6 (genetics) |
| 3 | Interleukin 1 Receptor Antagonist Protein (therapeutic use) |
| 3 | Injections, Intravenous |
| 3 | Inflammation (drug therapy) |
| 3 | Immunosuppressive Agents (pharmacology) |
| 3 | Immunomodulation |
| 3 | Giant Cell Arteritis (therapy) |
| 3 | Giant Cell Arteritis (immunology) |
| 3 | Giant Cell Arteritis (diagnosis) |
| 3 | French |
| 3 | Etanercept (adverse effects) |
| 3 | Enzyme-Linked Immunosorbent Assay |
| 3 | Efficiency |
| 3 | Drug Hypersensitivity (therapy) |
| 3 | Cytokines |
| 3 | Cytokines (metabolism) |
| 3 | Cytokines (immunology) |
| 3 | Cytokines (blood) |
| 3 | Cross-Sectional Studies |
| 3 | Comorbidity |
| 3 | Cell Proliferation (drug effects) |
| 3 | Case-Control Studies |
| 3 | Biological Therapy (methods) |
| 3 | Bibliographic review |
| 3 | Arthritis, Rheumatoid (physiopathology) |
| 3 | Antirheumatic Agents (pharmacokinetics) |
| 3 | Antirheumatic Agents (immunology) |
| 3 | Anti-TNF |
| 3 | Anakinra |
| 3 | Adult-onset Still's disease |
| 3 | Adalimumab (adverse effects) |
| 2 | uveitis |
| 2 | treatment |
| 2 | rapamycin |
| 2 | polymyalgia rheumatica |
| 2 | mycophenolate mofetil |
| 2 | interleukin-6 |
| 2 | interferon |
| 2 | infliximab |
| 2 | inflammation |
| 2 | eular recommendations |
| 2 | corticosteroids |
| 2 | azathioprine |
| 2 | adalimumab |
| 2 | Withholding Treatment |
| 2 | Viral Load (drug effects) |
| 2 | Vasculitis (drug therapy) |
| 2 | Ustekinumab (therapeutic use) |
| 2 | Tumor necrosis factor α |
| 2 | Tumor Necrosis Factor Inhibitors (therapeutic use) |
| 2 | Tomography, X-Ray Computed |
| 2 | Tomography, X-Ray Computed (methods) |
| 2 | Th17 Cells (pathology) |
| 2 | Th17 Cells (drug effects) |
| 2 | Takayasu Arteritis (therapy) |
| 2 | Takayasu Arteritis (pathology) |
| 2 | Takayasu Arteritis (immunology) |
| 2 | Takayasu Arteritis (diagnostic imaging) |
| 2 | Takayasu Arteritis (diagnosis) |
| 2 | Takayasu Arteritis (complications) |
| 2 | T-Lymphocytes, Regulatory (metabolism) |
| 2 | T-Lymphocytes, Regulatory (drug effects) |
| 2 | Synovitis (drug therapy) |
| 2 | Syndrome |
| 2 | Survival Analysis |
| 2 | Still's Disease, Adult-Onset (immunology) |
| 2 | Statistics, Nonparametric |
| 2 | Skin Neoplasms (chemically induced) |
| 2 | Sjögren syndrome |
| 2 | Sjogren's Syndrome (drug therapy) |
| 2 | Signal Transduction (drug effects) |
| 2 | Scleroderma, Systemic (complications) |
| 2 | Sampling Studies |
| 2 | Salvage Therapy |
| 2 | Remission Induction (methods) |
| 2 | Receptors, Interleukin-6 (genetics) |
| 2 | Pyrimidines (therapeutic use) |
| 2 | PubMed |
| 2 | Psoriasis (drug therapy) |
| 2 | Proportional Hazards Models |
| 2 | Polymyalgia Rheumatica (diagnosis) |
| 2 | Polymyalgia Rheumatica (blood) |
| 2 | Polymorphism, Single Nucleotide |
| 2 | Polyethylene Glycols (therapeutic use) |
| 2 | Polychondritis, Relapsing (immunology) |
| 2 | Polychondritis, Relapsing (complications) |
| 2 | Peptides |
| 2 | Peptides, Cyclic (immunology) |
| 2 | Patient Safety |
| 2 | Osteoporosis |
| 2 | Osteocalcin (blood) |
| 2 | Opportunistic Infections (immunology) |
| 2 | Opportunistic Infections (diagnosis) |
| 2 | Opportunistic Infections (chemically induced) |
| 2 | Neuromyelitis Optica (immunology) |
| 2 | Neuromyelitis Optica (drug therapy) |
| 2 | Neoplasms (immunology) |
| 2 | Neoplasms (chemically induced) |
| 2 | Molecular Targeted Therapy |
| 2 | Mice, Inbred C57BL |
| 2 | Methotrexate (pharmacology) |
| 2 | Methotrexate (adverse effects) |
| 2 | Medicine |
| 2 | Medication Therapy Management |
| 2 | Maintenance Chemotherapy (methods) |
| 2 | Macrophage Activation Syndrome (etiology) |
| 2 | Macrophage Activation Syndrome (chemically induced) |
| 2 | Lymphohistiocytosis, Hemophagocytic |
| 2 | Lymphohistiocytosis, Hemophagocytic (complications) |
| 2 | Lung (diagnostic imaging) |
| 2 | Logistic Models |
| 2 | Lipid Metabolism (drug effects) |
| 2 | Leukocytes, Mononuclear (metabolism) |
| 2 | Leukocytes, Mononuclear (drug effects) |
| 2 | Killer Cells, Natural (immunology) |
| 2 | Kaplan-Meier Estimate |
| 2 | Joints (drug effects) |
| 2 | Interleukins (immunology) |
| 2 | Interleukins (antagonists & inhibitors) |
| 2 | Interleukin-6 |
| 2 | Interleukin-6 Receptor alpha Subunit (metabolism) |
| 2 | Infliximab |
| 2 | Infliximab (adverse effects) |
| 2 | Inflammation (pathology) |
| 2 | Inflammation (immunology) |
| 2 | Immunosuppressive Agents (adverse effects) |
| 2 | Immunologic Factors (adverse effects) |
| 2 | Immunoglobulins, Intravenous (therapeutic use) |
| 2 | Immunoglobulin Fab Fragments (therapeutic use) |
| 2 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use) |
| 2 | Hospitals, University |
| 2 | Herpesvirus 4, Human |
| 2 | Herpesvirus 4, Human (isolation & purification) |
| 2 | Herpes zoster |
| 2 | Health Status |
| 2 | Glucocorticoids (pharmacology) |
| 2 | Giant Cell Arteritis (etiology) |
| 2 | Giant Cell Arteritis (complications) |
| 2 | Genetic Predisposition to Disease |
| 2 | Fluorodeoxyglucose F18 |
| 2 | Flow Cytometry |
| 2 | Fatigue (etiology) |
| 2 | Evidence-Based Medicine |
| 2 | Europe |
| 2 | Europe (epidemiology) |
| 2 | Edema (pathology) |
| 2 | Drugs, Investigational (therapeutic use) |
| 2 | Drug Therapy, Combination (methods) |
| 2 | Drug Resistance (drug effects) |
| 2 | Drug Hypersensitivity (etiology) |
| 2 | Drug Eruptions |
| 2 | Desensitization, Immunologic |
| 2 | Dermatology |
| 2 | Cytokines (antagonists & inhibitors) |
| 2 | Crohn Disease (drug therapy) |
| 2 | Corticosteroid |
| 2 | Collagen Type II (blood) |
| 2 | Certolizumab pegol |
| 2 | Certolizumab Pegol |
| 2 | Cell Line, Tumor |
| 2 | Cell Count |
| 2 | Castleman Disease (pathology) |
| 2 | Castleman Disease (diagnosis) |
| 2 | Cartilage, Articular (drug effects) |
| 2 | Cardiovascular Diseases (prevention & control) |
| 2 | Cardiovascular Diseases (blood) |
| 2 | Canakinumab |
| 2 | Bone and Bones (pathology) |
| 2 | Biomarkers |
| 2 | Biomarkers (metabolism) |
| 2 | Biologics |
| 2 | Biological Products (pharmacology) |
| 2 | Bayes Theorem |
| 2 | B-Lymphocyte |
| 2 | B cells |
| 2 | Autoimmunity |
| 2 | Autoimmune disease |
| 2 | Autoimmune Diseases (drug therapy) |
| 2 | Arthritis, Rheumatoid (virology) |
| 2 | Arthritis, Rheumatoid (psychology) |
| 2 | Arthritis, Rheumatoid (mortality) |
| 2 | Arthritis, Rheumatoid (genetics) |
| 2 | Arthritis, Psoriatic (drug therapy) |
| 2 | Arthritis, Juvenile (physiopathology) |
| 2 | Arthritis, Juvenile (immunology) |
| 2 | Arthritis, Juvenile (diagnosis) |
| 2 | Arthritis, Infectious (drug therapy) |
| 2 | Arthritis, Experimental (pathology) |
| 2 | Arthralgia (physiopathology) |
| 2 | Arteritis |
| 2 | Apyrase (metabolism) |
| 2 | Aortitis (drug therapy) |
| 2 | Aortitis (diagnostic imaging) |
| 2 | Antirheumatic Agents (economics) |
| 2 | Antirheumatic Agents (blood) |
| 2 | Antiinflammatory agent |
| 2 | Antigens, CD (metabolism) |
| 2 | Antibodies, Monoclonal, Humanized (pharmacokinetics) |
| 2 | Antibodies, Monoclonal, Humanized (immunology) |
| 2 | Antibodies, Monoclonal, Humanized (blood) |
| 2 | Antibodies, Monoclonal (pharmacology) |
| 2 | Antibodies, Monoclonal (immunology) |
| 2 | Antibodies, Monoclonal (blood) |
| 2 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
| 2 | Anti-Inflammatory Agents, Non-Steroidal (adverse effects) |
| 2 | Anti-Inflammatory Agents (adverse effects) |
| 2 | Ankylosing spondylitis |
| 2 | Amyloidosis (drug therapy) |
| 2 | Abatacept (administration & dosage) |
| 1 | visual acuity/drug effect |
| 1 | uveitis/ drug therapy |
| 1 | tumor necrosis factor-alpha/antagonist & inhibitor |
| 1 | tumor necrosis factor-alfa inhibitors |
| 1 | treatment planning |
| 1 | treatment outcome |
| 1 | tomography |
| 1 | systemic glucocorticoid therapy |
| 1 | steroid |
| 1 | sarcoidosis |
| 1 | risk |
| 1 | retina/anatomy & histology/drug effect |
| 1 | remission |
| 1 | regulatory T cells |
| 1 | registry regate registry |
| 1 | receptor |
| 1 | prospective follow-up |
| 1 | photometry |
| 1 | pharmacokinetics |
| 1 | perimetry |
| 1 | perforin |
| 1 | paradoxical reactions |
| 1 | optimal design |
| 1 | optical coherence |
| 1 | non-linear mixed effects model |
| 1 | nephropathy |
| 1 | natural killer cells |
| 1 | multimodal imaging |
| 1 | monoclonal |
| 1 | modifying antirheumatic drugs |
| 1 | methotrexate |
| 1 | management |
| 1 | magnetic field |
| 1 | macular edema |
| 1 | macular edema/drug therapy |
| 1 | laser flare photometry |
| 1 | interleukin |
| 1 | interleukin-6/antagonist & inhibitor |
| 1 | interleukin-6 receptor inhibition |
| 1 | interleukin-6 inhibitor |
| 1 | infusion-related reactions |
| 1 | inadequate response |
| 1 | immunosuppressive agent |
| 1 | immunosuppressive agent/ therapeutic use |
| 1 | il-6 receptor subunits |
| 1 | humanized/ therapeutic use |
| 1 | hidradenitis suppurativa |
| 1 | granzyme |
| 1 | female |
| 1 | factor-alpha inhibitors |
| 1 | electroretinography |
| 1 | drug indication |
| 1 | drug effect |
| 1 | diseases |
| 1 | disease-activity |
| 1 | dendritic cell |
| 1 | danish danbio registry |
| 1 | cytokines |
| 1 | cytokine |
| 1 | corticosteroid |
| 1 | controlled-trial |
| 1 | clinical-practice |
| 1 | clinical evaluation |
| 1 | cerebrospinal fluid |
| 1 | central nervous system |
| 1 | cardiovascular risk |
| 1 | cancer recurrence |
| 1 | canakinumab |
| 1 | biologics |
| 1 | biological therapy |
| 1 | biological product |
| 1 | biological agents |
| 1 | biological DMARDs |
| 1 | biologic agents |
| 1 | bayesian fisher information matrix |
| 1 | apolipoprotein |
| 1 | antibody |
| 1 | anti-TNF drug |
| 1 | anakinra |
| 1 | aged |
| 1 | adult |
| 1 | adult-onset Still\textquoterights disease |
| 1 | adrenal cortex hormones/therapeutic use |
| 1 | adipokine |
| 1 | West |
| 1 | Voriconazole (therapeutic use) |
| 1 | Vitrectomy |
| 1 | Vitiligo (pathology) |
| 1 | Vitamins (pharmacology) |
| 1 | Vitamin D (pharmacology) |
| 1 | Vital Capacity |
| 1 | Vital Capacity (drug effects) |
| 1 | Visual Acuity (drug effects) |
| 1 | Virus Activation |
| 1 | Virus Activation (immunology) |
| 1 | Viral hepatitis B |
| 1 | Vasculitis (physiopathology) |
| 1 | Vaccination |
| 1 | Uveitis |
| 1 | Uveitis (therapy) |
| 1 | Uveitis (physiopathology) |
| 1 | Uveitis (pathology) |
| 1 | Uveal melanoma |
| 1 | Uveal Neoplasms (pathology) |
| 1 | Uveal Neoplasms (metabolism) |
